Marianna Gaça of British American Tobacco’s Group Research and Development has been successfully voted onto the Board of Directors of the American Society for Cellular and Computational Toxicology (ASCCT). ASCCT was established jointly by Institute of In Vitro Sciences (IIVS) and Physicians Committee for Responsible Medicine (PCRM) and launched at the IIVS Toxicology Forum, Maryland USA in October 2010.
‘I know that I can speak for my fellow board members when I say that we are all looking forward to working together to increase the membership and impact of the society’s activities’, said ASCCT secretary Kristie Sullivan of the PCRM.
The society has currently just over 100 individual members and 12 institutional sponsors, including scientists from the cosmetics, pharma, chemical and tobacco industries, CROs, SMEs, NGOs, federal agencies, journalists, regulators and animal welfare groups.
‘We are thrilled to be involved with the ASCCT at Board level and look forward to supporting and driving the ASCCT vision in the coming years’, said Marianna Gaça, BAT’s ASSCT Board representative. ‘We hope this opportunity will further encourage science collaboration to support our science base and increase awareness of emerging areas of science ‘.
British American Tobacco’s GR&D Centre has established an in-house research programme including the development of in vitro cellular and computational methodologies to facilitate the understanding of the biological effects of tobacco smoke and, in the future, help support the assessment of conventional and modified risk tobacco products.
ASCCT Officers include Roger Curren (IIVS) as president, Erin Hill (IIVS) as treasurer and Krisitie Sullivan (PCRM). Recently voted Board Directors include Marilyn Aardema (Marilyn Aardema Consulting, Inc. USA); Jack Fowle (formerly Environmental Protection Agency) and Thomas Hartung (Center for Alternatives for Animal Testing (CAAT), John Hopkins University USA).
Notes to Editors
About British American Tobacco: British American Tobacco is a global tobacco and Next Generation Product company with brands sold in more than 200 markets. It employs more than 50,000 people worldwide and has over 200 brands in its portfolio, with its cigarettes chosen by one in eight of the world’s one billion smokers. Leading global brands include Dunhill, Kent, Pall Mall and Lucky Strike.
About Next Generation Products (NGP): Next Generation Products is part of the British American Tobacco Group and is focused on developing and delivering high-quality alternative nicotine and tobacco products for adult consumers in the key areas of Vapour, Oral and Tobacco Heating Products. For more information see www.goVype.com and www.bat-science.com.
About Tobacco Harm Reduction: The only way to avoid the risks associated with tobacco use is not to consume tobacco at all, and the best way to reduce the risks is to stop using tobacco. However, the concept of harm reduction is increasingly being considered in relation to tobacco use. Harm reduction is about finding practical ways to minimise the health impact of an inherently risky activity or behaviour, without seeking to stop it entirely. It is a key element of BAT’s business strategy and is being discussed by some regulators. We think it’s important to work towards producing consumer-acceptable, potentially reduced risk products. We believe that tobacco regulatory policies should include harm reduction approaches for the millions of adults globally who will continue to consume tobacco products.
The Public Health Impact of e-cigarettes: Many in the public health community believe e-cigarettes offer great potential for contributing to tobacco harm reduction policies. A 2018 updated evidence review by Public Health England*, an executive body of the UK Department of Health, concludes that vaping is around 95% less harmful than smoking cigarettes. The UK’s Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer than smoking and that they should be widely promoted as a substitute for smoking.
For more information: email Joanna_Hunt@bat.com or call +44 (0)7858 375461